Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Samantha Semenkow
Citi

Samantha Semenkow

Citi
Wall Street Analyst
★★☆☆☆
#2672
on 13Foresight · ranked by our own returns
53%
Success Rate
-1.9%
Average Return
36 of 68 calls profitable · -6.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 53% of Samantha Semenkow's ratings turned a profit when each position was held for 2 year — averaging -1.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

90 Buy 3 Hold 2 Sell
Samantha's Stock Coverage 27 ratings · 2026-11-06
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
ROIV
Roivant Sciences
 Oct 29, 2026 BUY Strong Buy
+10.7% avg upside
19 analysts
$56.00
51.68% Upside
 +1.9% ·
RYTM
Rhythm Pharmaceuticals
 Oct 28, 2026 BUY Strong Buy
+39.2% avg upside
23 analysts
$143.00
54.51% Upside
 +14.2% ·
ARGX
Argenx Se
 Oct 28, 2026 BUY Strong Buy
-8.2% avg upside
48 analysts
$1232.00
37.89% Upside
 +4.0% ·
AGIO
Agios Pharma
 Oct 28, 2026 BUY Strong Buy
+99.0% avg upside
30 analysts
$52.00
70.23% Upside
 -22.9% ·
BEAM
Beam Therapeutics
 Oct 27, 2026 BUY Strong Buy
+91.2% avg upside
25 analysts
$68.00
149.76% Upside
 +3.9% ·
SYRE
Spyre Therapeutics
 Oct 21, 2026 BUY Strong Buy
+0.9% avg upside
25 analysts
$119.00
23.22% Upside
 +3.9% ·
BIOA
BioAge Labs, Inc.
 Oct 14, 2026 BUY Strong Buy
+506.9% avg upside
9 analysts
$21.00
257.79% Upside
 +2.2% ·
CGEM
Cullinan Management
 Oct 06, 2026 BUY Strong Buy
+135.1% avg upside
16 analysts
$33.00
119.55% Upside
 -30.4% ·
NKTR
Nektar Therapeutics
 Oct 05, 2026 BUY Strong Buy
+97.0% avg upside
26 analysts
$151.00
288.45% Upside
 -8.9% ·
BHVN
Biohaven Ltd.
 Sep 17, 2026 BUY Buy
+51.3% avg upside
25 analysts
$17.00
10.32% Upside
 +1.8% ·
DNTH
Dianthus Therapeutics
 Sep 04, 2026 BUY Strong Buy
+23.4% avg upside
32 analysts
$156.00
89.45% Upside
 -23.2% ·
CABA
Cabaletta Bio
 Sep 01, 2026 BUY Strong Buy
+832.3% avg upside
16 analysts
$10.00
562.21% Upside
 -56.7% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Aug 10, 2026 BUY Strong Buy
+373.2% avg upside
17 analysts
$97.00
343.58% Upside
 -64.5% ·
WVE
Wave Life Sciences
 Jul 31, 2026 BUY Strong Buy
+443.6% avg upside
30 analysts
$19.00
429.18% Upside
 -38.8% ·
LRMR
Larimar Therapeutics
 Jun 30, 2026 BUY Strong Buy
+621.1% avg upside
22 analysts
$14.00
466.84% Upside
 -22.3% ·
IMVT
Immunovant
 Jun 30, 2026 BUY Strong Buy
+38.4% avg upside
25 analysts
$61.00
109.20% Upside
 -26.3% ·
SABS
SAB Biotherapeutics
 Jun 15, 2026 BUY Strong Buy
+218.4% avg upside
14 analysts
$11.00
228.43% Upside
 -18.5% ·
ALLO
Allogene Therapeutics
 Apr 09, 2026 BUY Strong Buy
+1186.8% avg upside
28 analysts
$4.00
238.97% Upside
 -62.5% ·
VYGR
Voyager Therapeutics
 Mar 23, 2026 BUY Strong Buy
+730.1% avg upside
23 analysts
$11.00
539.45% Upside
 -54.1% ·
MLTX
MoonLake Immunotherapeutics
 Mar 20, 2026 SELL Strong Buy
+158.9% avg upside
20 analysts
$6.00
49.12% Downside
 +29.1% ·
SANA
Sana Biotechnology
 Mar 04, 2026 BUY Strong Buy
+282.6% avg upside
14 analysts
$12.00
366.98% Upside
 -38.7% ·
PRME
Prime Medicine, Inc.
 Nov 11, 2025 HOLD Strong Buy
+101.7% avg upside
18 analysts
$4.25
10.01% Downside
 +13.5% ·
EDIT
Editas Medicine
 Mar 06, 2025 BUY Buy
+398.5% avg upside
33 analysts
$5.00
87.34% Upside
 +43.3% ·
FTH
Faeth Therapeutics
 Jun 03, 2024 BUY Strong Buy
+160.4% avg upside
22 analysts
$4.00
78.54% Downside
 +8.8% ·
NMTRQ
9 Meters Biopharma
 May 18, 2023 HOLD Buy
+3234374900.0% avg upside
11 analysts
$0.75
74999899.98% Upside
 · ·
ZLAB
Zai Lab
 May 11, 2023 BUY Strong Buy
+170.4% avg upside
13 analysts
$130.00
489.12% Upside
 -20.3% ·
ARDX
Ardelyx
 Jul 21, 2021 BUY Strong Buy
+324.3% avg upside
21 analysts
$7.00
130.95% Upside
 +82.3% ·
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Samantha Semenkow — Frequently Asked Questions
How accurate are Samantha Semenkow's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Samantha's ratings were profitable over a one-year hold, with an average return of -6.3% per rating, or -11.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Samantha ranked on 13Foresight?
Samantha Semenkow is currently ranked #2672 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Samantha cover?
Samantha most recently has ratings on ROIV, RYTM, ARGX, AGIO, BEAM, SYRE, BIOA, CGEM, NKTR, BHVN, DNTH, CABA and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.